Lanier Ohare
Adult Health · Birmingham, ALNPI 1649681453
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (51.4%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. Boehringer Ingelheim accounts for 93.8% of it on its own, with 7 other manufacturers making up the rest. Among adult health clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 67 payments — averaging $623.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$39K
- AbbVie$2K
- United Therapeutics Corporation$170
- Eisai Inc.$121
- GSK$118
- AstraZeneca$83
- plus $120 from 2 others
What the payments were for
- Consulting fees$21,47851%
- Speaking & faculty fees$10,75526%
- Travel & lodging$7,25617%
- Food & beverage$2,2815%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 56 | $39,164 |
| AbbVie | 2 | $1,993 |
| United Therapeutics Corporation | 3 | $170 |
| Eisai Inc. | 1 | $121 |
| GSK | 1 | $118 |
| AstraZeneca | 1 | $83 |
| Philips North America LLC | 1 | $74 |
| Mallinckrodt Hospital Products Inc. | 2 | $46 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$41,770 in reported general payments places this provider in the 95th percentile of 308 adult health providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 49 | $694,783 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 25 | $20,632 |
| Breo ElliptaFluticasone/Vilanterol | 29 | $12,013 |
| Incruse ElliptaUmeclidinium Bromide | 25 | $8,232 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 13 | $7,949 |
| Mycophenolate Mofetil | 52 | $6,099 |
| Hydroxychloroquine Sulfate | 114 | $5,183 |
| Wixela InhubFluticasone Propion/Salmeterol | 20 | $4,171 |
| Arnuity ElliptaFluticasone Furoate | 11 | $4,149 |
| BreynaBudesonide/Formoterol Fumarate | 16 | $4,003 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 11 | $3,237 |
| SymbicortBudesonide/Formoterol Fumarate | 13 | $2,808 |
| Esomeprazole Magnesium | 14 | $2,587 |
| MethotrexateMethotrexate Sodium | 60 | $1,431 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 64 | $1,411 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev | $39,164 | $694,78349 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta | $118 | $45,02690 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $83 | $10,75626 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 308 adult health providers in Alabama.
Other adult health in Birmingham
- Jessica WrightBirmingham$33K
- Sara HopperBirmingham$21K
- Andrea SuttonBirmingham$21K
- Laura RomundstadBirmingham$10K
- Jane DavisBirmingham$9K
- Anissa ThomasBirmingham$8K
- Chelsey KahlerBirmingham$5K
- Mary WadeBirmingham$5K
- Merry WoodsBirmingham$4K
- Taneaka Rowe-HouserBirmingham$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.